Cyst fluid metabolites distinguish malignant from benign pancreatic cysts.

ABSTRACT:

Objectives

Current standard of care imaging, cytology, or cystic fluid analysis cannot reliably differentiate malignant from benign pancreatic cystic neoplasms. This study sought to determine if the metabolic profile of cystic fluid could distinguish benign and malignant lesions, as well as mucinous and non-mucinous lesions.

Methods

Metabolic profiling by untargeted mass spectrometry and quantitative nuclear magnetic resonance was performed in 24 pancreatic cyst fluid from surgically resected samples with pathological diagnoses and clinicopathological correlation.

Results

(Iso)-butyrylcarnitine distinguished malignant from benign pancreatic cysts, with a diagnostic accuracy of 89%. (Iso)-butyrylcarnitine was 28-fold more abundant in malignant cyst fluid compared with

SUBMITTER: Shi J 

PROVIDER: S-EPMC8479274 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature